quantitative mgmt promoter methylation analysis  (Pyrosequencing Inc)

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 102 Primary Glioblastoma MGMT Unmethylated Patients With Substratification by MGMT Values

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Biomarker Discovery

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Kaplan-Meier analysis is used to A, compare the MGMT (1-1.99) vs MGMT (<1) and MGMT (≥2) patients. The MGMT (1-1.99) group’s median OS (25.4 months) falls in between the MGMT (≥2) (38.8 months) and MGMT (<1) (17.3 months) median OS values (Log-rank P = .001). B, PFS showed the same trend, namely the MGMT (1-1.99) group generated a higher median OS of 11.8 months compared to the MGMT (<1) group but lower than the MGMT (≥ 2) group, yielding 11.8 months vs 7.92 months and 18.0 months (Log-rank P < .0001), respectively. MGMT indicates O-6-methylguanine-DNA methyltransferase; mo, months; OS, overall survival; PFS, progression-free survival.

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Generated

Journal: Neuro-Oncology Practice

Article Title: Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival

doi: 10.1093/nop/npy028

Figure Lengend Snippet: Cox Regression Analysis of Overall Survival and Progression-Free Survival of 165 Primary Glioblastoma Patients With Substratification by MGMT Values

Article Snippet: Our patient cohort was derived retrospectively and consisted of newly diagnosed GBM patients seen at UCLA and KPLA between 2011 and 2016 with accessible LabCorp quantitative MGMT methylation values.

Techniques: Biomarker Discovery

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Detection of MGMT promoter methylation in glioblastoma using pyrosequencing

doi:

Figure Lengend Snippet: Pyrograms for MGMT methylation pyrosequencing test from the brain tissues of an epilepsy patient (Panel A) and a glioma patient (Panel B).

Article Snippet: In this study, we sought to develop and validate a quantitative MGMT methylation assay using pyrosequencing on glioblastoma.

Techniques: Methylation

Journal: International Journal of Clinical and Experimental Pathology

Article Title: Detection of MGMT promoter methylation in glioblastoma using pyrosequencing

doi:

Figure Lengend Snippet: Mean MGMT methylation of tissue specimens from epilepsy patients (E1-E10) and glioma patients (G1-G43). The dash line represents a 10% cutoff.

Article Snippet: In this study, we sought to develop and validate a quantitative MGMT methylation assay using pyrosequencing on glioblastoma.

Techniques: Methylation